Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).

William G. Wierda,Jennifer R. Brown,Stephan Stilgenbauer,Steven Coutre,John C. Byrd,Anthony R. Mato,Constantine S. Tam,Jacqueline C. Barrientos,Ulrich Jäger,Stephen Devereux,Florence Cymbalista,Paul M. Barr,Claire Dearden,Marco Montillo,Carol Moreno,Emily Liu,Anita Szoke,James P. Dean,Susan OBrien

Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).

2018

William G. Wierda
Jennifer R. Brown
Stephan Stilgenbauer
Steven Coutre
John C. Byrd
Anthony R. Mato
Constantine S. Tam
Jacqueline C. Barrientos
Ulrich Jäger
Stephen Devereux
Florence Cymbalista
Paul M. Barr
Claire Dearden
Marco Montillo
Carol Moreno
Emily Liu
Anita Szoke
James P. Dean
Susan OBrien

7521Background: B2M is often elevated in pts with CLL and correlates with disease stage and burden. Normalization of B2M at 6 mo during ibr treatment was associated with improved progression-free s...

Keywords:

Chronic lymphocytic leukemia
Beta-2 microglobulin
Cancer research
Pathology
Medicine
Ibrutinib
Oncology
Internal medicine
relapsed refractory
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations